In a clinical context, a global Phase 3 trial of ASP‐1929, an anti‐epidermal growth factor receptor (EGFR) antibody IR700 conjugate for recurrent or inoperable head and neck cancer patients, is currently ongoing (NCT03769506). Here, EGFR is linked to head and neck cancer.